Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
10.1 EUR | +5.21% | +0.50% | +137.09% |
04-12 | Nyxoah Names New Chief Medical Officer | MT |
04-12 | Nyxoah S.A. Appoints Maurits Boon as Chief Medical Officer | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+137.09% | 294M | - | ||
+8.14% | 219B | B | ||
+6.80% | 183B | B- | ||
+11.39% | 133B | B- | ||
+26.05% | 108B | A- | ||
+1.44% | 63.06B | A- | ||
+12.22% | 52.02B | B+ | ||
-0.62% | 48.2B | B+ | ||
-0.47% | 40.37B | A | ||
+13.00% | 39.35B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NYXH Stock
- Ratings Nyxoah SA